A Phase 1 Study to Evaluate the Safety and Immunogenicity of GC4006A in Healthy Adults | NCT07728396

NCT07728396

Overview

NCT ID: NCT07728396
Lead Sponsor: GC Biopharma CorpINDUSTRY
Official Title: A Phase 1, Randomized, Double-blind, Dose-Escalation, Placebo-Controlled, Multicenter Clinical Trial to Evaluate the Safety and Immunogenicity of the COVID-19 Preventive Vaccine 'GC4006A' in Healthy Adults Aged 19 to 64 Years
Brief Summary: A Phase 1, Randomized, Double-blind, Dose-Escalation, Placebo-Controlled, Multicenter Clinical Trial to Evaluate the Safety and Immunogenicity of the COVID-19 Preventive Vaccine 'GC4006A' in Healthy Adults Aged 19 to 64 Years
Conditions: COVID - 19
Interventions: GC4006A
Normal Saline

Ages Eligible for Study: Adult (18-64)
Sexes Eligible for Study: All
Accepts Healthy Volunteers?: Yes
Eligibility Criteria: Inclusion Criteria:

Age 19-64 with written informed consent

≥16 weeks since last COVID-19 vaccination

Exclusion Criteria:

Positive SARS-CoV-2 test (RT-PCR/Rapid Antigen) at screening or randomization

<16 weeks since COVID-19 diagnosis

History of serious adverse event, allergy, or hypersensitivity to the vaccines

Pregnant or lactating women